Castellani RJ

References (2)

Title : Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit - Hoilund-Carlsen_2024_Ageing.Res.Rev__102348
Author(s) : Hoilund-Carlsen PF , Alavi A , Barrio JR , Castellani RJ , Costa T , Herrup K , Kepp KP , Neve RL , Perry G , Revheim ME , Robakis NK , Sensi SL , Vissel B
Ref : Ageing Res Rev , :102348 , 2024
Abstract :
PubMedSearch : Hoilund-Carlsen_2024_Ageing.Res.Rev__102348
PubMedID: 38830549

Title : Current approaches in the treatment of Alzheimer's disease - Shah_2008_Biomed.Pharmacother_62_199
Author(s) : Shah RS , Lee HG , Xiongwei Z , Perry G , Smith MA , Castellani RJ
Ref : Biomed Pharmacother , 62 :199 , 2008
Abstract :
PubMedSearch : Shah_2008_Biomed.Pharmacother_62_199
PubMedID: 18407457